

HB 3817-1  
(LC 4313)  
3/28/25 (SCT/ps)

Requested by Representative SKARLATOS

**PROPOSED AMENDMENTS TO  
HOUSE BILL 3817**

1 On page 1 of the printed bill, line 2, delete “; creating new provisions;  
2 and amending ORS 475.005”.

3 Delete lines 4 through 26 and delete pages 2 through 6 and insert:

4 **“SECTION 1. (1) As used in this section, ‘ibogaine’ means a na-**  
5 **turally occurring indole alkaloid extracted from the root bark of the**  
6 **Tabernanthe iboga shrub.**

7 **“(2) The Oregon Health Authority and the Department of Veterans’**  
8 **Affairs shall study the consumption of ibogaine by individuals who**  
9 **have post-traumatic stress disorder, major depressive disorder, an**  
10 **anxiety disorder or substance use disorder for the purpose of treating**  
11 **the disorder. The authority and the department shall submit a report**  
12 **in the manner provided by ORS 192.245, and may include recommen-**  
13 **dations for legislation, to the interim committees of the Legislative**  
14 **Assembly related to health care no later than September 15, 2029. The**  
15 **report must include information about and recommendations on the**  
16 **following:**

17 **“(a) The available medical, psychological and scientific studies, re-**  
18 **search and other data relating to the safety and efficacy of ibogaine;**

19 **“(b) The sourcing and production of ibogaine;**

20 **“(c) Recommended doses and delivery methods of ibogaine;**

21 **“(d) Testing and safety of ibogaine products;**

**“(e) Best practices for client and public health and safety, including client data protection and client consent;**

**“(f) Training and requirements for individuals who administer ibogaine to clients;**

**“(g) Requirements for how ibogaine is administered to clients and how clients are prepared and supported through the duration of and after administration;**

**“(h) Requirements for a system to track ibogaine and locations at which ibogaine will be produced, stored and administered or consumed;**

**“(i) Client screening and eligibility requirements for consumption of ibogaine, and any conditions that would cause a client to be ineligible;**

**“(j) Funding mechanisms for the administration of an ibogaine program and the long-term sustainability of the program; and**

**“(k) Reporting of data on ibogaine consumption and client outcomes.**

**“SECTION 2. Section 1 of this 2025 Act is repealed on January 2, 2030.”.**